Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

This study compares two treatments — pacritinib (a newer targeted drug) versus hydroxyurea (a standard drug) — in people with a rare blood cancer called proliferative chronic myelomonocytic leukemia (CMML), where the white blood cell count is dangerously elevated. **You may be eligible if...** - You have been diagnosed with CMML-1 (a specific, early form of this blood cancer) - Your white blood cell count is 13 billion per litre or higher - Your disease is considered advanced, shown by an enlarged spleen, significant symptoms, or low platelet count **You may NOT be eligible if...** - You have more than 10% blast cells (immature cancer cells) in your bone marrow - Your disease does not meet the criteria for advanced or proliferative CMML - You have significant other health conditions that affect eligibility Talk to your doctor to see if this trial is right for you.